A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Study Evaluating the Safety and Efficacy of Lb-P8 in Patients with Primary Sclerosing Cholangitis (Psc)

Study on Investigational Medication for PSC (Primary Sclerosing Cholangitis)

R
Raj Vuppalanchi, MD

Primary Investigator

Enrolling By Invitation
18 years - 75 years
All
Phase 2
1 participants needed
1 Location

Brief description of study

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

THIS STUDY IS ENROLLING BY INVITATION ONLY

Detailed description of study

This is phase 2, randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of LB-P8 in adult patients with primary sclerosing cholangitis(PSC).

  • Part 1 will evaluate safety and tolerability of 2 pre-selected dose level of LB-P8 (low-dose[1×10^10 CFU/capsule] and high dose [1×10^11 CFU/capsule]) in adult patients with PSC. Part 1 plans to enroll a maximum number of 12 patients based on a "3+3" study design.
  • Part 2 will evaluate safety and efficacy in adult patients with PSC. Eligible patients with PSC will be randomized in a 1:1:1 ratio to receive treatment with low-dose LB-P8(1×10^10 CFU/capsule), high-dose LB-P8(1×10^11 CFU/capsule) or matched placebo capsule. Part 2 plans to enroll and randomize 75 patients to obtain 60 evaluable patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Primary Sclerosing Cholangitis, PSC
  • Age: 18 years - 75 years
  • Gender: All

Inclusion Criteria:

  • Age: 18 to 75 years
  • A diagnosis of PSC based on cholangiographic evidence of PSC in accordance with American Association for the Study of Liver Diseases (AASLD) guidelines
  • ALP >1.5 times the ULN at screening
  • PSC with or without IBD, such as ulcerative colitis or Crohn's disease
  • If patients are being administered biologic or advanced therapeutic treatments, immunosuppressants, systemic corticosteroids, obeticholic acid, fibrates, or statins, they must be on a stable dose for ≥3 months prior to, and including, Day 0 and plan to remain on a stable dose throughout the study
  • If patients are receiving ursodeoxycholic acid, they must be on a stable dose (not exceeding 23 mg/kg/day) for >3 months prior to screening
  • Patient agrees to stop all probiotics for at least 2weeks prior to treatment
  • Patient is unable to conceive and/or patient who's partner is unable to become pregnant and/or agree to use effective methods of contraception when engaging in heterosexual intercourse

Exclusion Criteria:

  • Treatment with any investigational agents within 3 months or 5 half-lives, whichever is longer prior to treatment or during the study. Gene therapy or other long-lasting investigational agents with unknown half-life is not allowed
  • History of a liver transplant or anticipated need for a liver transplant within 1 year
  • Patients who show evidence of significant worsening of hepatic function will be excluded.
  • Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters
  • Model for end-stage liver disease (MELD) score as below, unless the MELD is driven by anticoagulant therapy, vitamin deficiency, or kidney disease:
  • MELD Score of >12 (decompensated cirrhosis) for Part 1 of the study
  • MELD Score of >12 for Part 2 of the study
  • Small-duct PSC (in the absence of large duct PSC)
  • Secondary causes of sclerosing cholangitis including IgG4 associated sclerosing cholangitis
  • Any history of cholangiocarcinoma, gallbladder cancer, or hepatocellular carcinoma
  • History of any malignancy with lymph node or regional metastases within 5 years or current malignancy undergoing active treatment
  • Patients who require chronic use of antibiotics, received antibiotics in the last 1 month, or received Rebyota or Vowst (applicable for patients with Clostridioides difficile infection)
  • In patients with ulcerative colitis, partial Mayo score of >6 or, patients with Crohn's disease if CDAI of >220
  • Chronic kidney injury
  • Recent acute cholangitis (within 90 days)
  • Patients with indwelling biliary drain (or stent), total proctocolectomy with ileal anal pouch, partial large bowel resections or history of small bowel resection
  • Other causes of liver disease, such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), AIH/PSC overlap syndrome, alpha-1-antitrypsin deficiency, viral hepatitis, iron overload syndrome, Wilson disease, nonalcoholic steatohepatitis, and/or alcohol related liver disease. Additionally, positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV) (detectable HCV RNA in the serum), or human immunodeficiency virus antibodies (anti HIV)
  • Active drug (known or suspected use of illicit drugs or drugs of abuse) or alcohol abuse disorder
  • Female patients who are pregnant, nursing, or planning to become pregnant during the study
  • Clinically significant and/or active infection
  • Subjects with a greater degree of immunosuppression, as evidenced by Alsolute neutrophil count <500 cells/mL or in the investigator's judgement immunosuppressed and at higher risk of infection

This study investigates the safety and effectiveness of an investigational medication for primary sclerosing cholangitis (PSC). PSC is a liver disease that causes inflammation and scarring of the bile ducts, which can lead to liver damage. This study involves two parts. In Part 1, the safety and tolerability of two doses of the investigational medication will be evaluated. In Part 2, the safety and effectiveness will be further assessed.

Participants will receive either a low dose, a high dose of the investigational medication, or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study is double-blind, meaning neither the participants nor the researchers know who receives the investigational medication or the placebo. Participants will be randomly assigned to one of the study arms.

  • Who can participate: Adults aged 18 to 75 years with primary sclerosing cholangitis and an ALP level greater than 1.5 times the upper limit of normal can participate. They must be on stable doses of current treatments for at least 3 months before and during the study.
  • Study details: Participants will be randomly assigned to receive either a low dose, a high dose of the investigational medication, or a placebo. The study is double-blind, meaning neither the participants nor the researchers know who receives which treatment.
Updated on 08 Jan 2026. Study ID: GI-LISCB-LB08-211, 27967
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

This study is accepting only persons who receive care at a certain clinic or doctor or who are part of an invited group. Questions about this study can be directed to the study team listed in the description or contact your doctor to see if you are eligible.

Accepting Referrals by Invitation Only